



HTA in a public crisis: communication challenges

Issue panel

ISPOR 18 May 2022

Session 312

With us today

1. Dr Saskia Knies

- Senior advisor health economics
National Health Care Institute, HTx Consortium


2. Bertalan Németh

- Principal Health Economist, Syreon
Research Institute, HTx Consortium

3. Dr Dalia Dawoud

- Senior Scientific Adviser, Science,
Policy and Research Programme,
National Institute for Health and Care
Excellence (NICE), HTx Consortium







During
COVID-19,
we all
witnessed

- Governments purchasing quantities of vaccines or medicines even before they were authorised, even before any health technology assessment
- HTA typically advises on
 - Relative efficacy of different vaccines or treatments
 - Which populations to benefit?
- Can it be made real-time? Can it inform decision makers and how?

First questions to the panel

1. How can HTA experts scan the horizon to be prepared to provide rapid reports for decision making? Is there a role for assessments at the EU level to achieve consistency and harmonise messages communicated to the public?
2. Can real-world data analysis help when clinical trial results contradict each other, or not provide enough information for all target populations?
3. How can HTA agencies respond to the rapidly changing evidence base where information can rapidly become obsolete and frequent updates are needed?
4. Misinformation and fake news are everywhere, how can HTA outcomes be communicated to the public against this backdrop?



And of course, your own
questions and experiences!

